Aging, Inflammatory Response
Conditions
Brief summary
This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.
Interventions
OTHERResistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Sponsors
National Taipei University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 60-75 years or older * No regular resistance training habit (defined as ≥2 sessions per week) in the past year * No musculoskeletal injuries within the past six months
Exclusion criteria
* Obesity (BMI \> 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes. * Regular use of anti-inflammatory medications (e.g., NSAIDs). * Smoking or alcohol abuse * Inability to safely perform the prescribed resistance exercise movements * Unable to fully comprehend the study information and instructions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in soluble IL-6 receptor concentration | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Soluble IL-6 receptor concentrations will be measured and reported in ng/mL. |
| Changes in soluble gp130 concentration | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Soluble gp130 concentrations will be measured and reported in ng/mL. |
| Changes in IL-10 concentration | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | IL-10 concentrations will be measured and reported in pg/mL. |
| Changes in IL-1RA concentration | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | IL-1RA concentrations will be measured and reported in pg/mL. |
| Changes in TNF-α concentration | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | TNF-α concentrations will be measured and reported in pg/mL. |
| Changes in IL-6 concentration | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Plasma IL-6 concentrations will be measured and reported in pg/mL. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in monocyte count | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Monocyte count will be measured and reported in cells/μL. |
| Body fat percentage | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Body fat percentage will be measured using a body composition analyzer and reported as a percentage. |
| Lean body mass | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Total lean body mass will be measured using a body composition analyzer and reported in kilograms. |
| Changes in gp130 (CD130) protein expression in PBMCs | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units. |
| Changes in STAT3 protein expression in PBMCs | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units. |
| Changes in phosphorylated STAT3 protein expression in PBMCs | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units. |
| Borgs Ratings of Perceived Exertion (RPE) | 1-hour during each exercise intervention | Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion). |
| Handgrip strength | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms. |
| Knee extension strength | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters. |
| 30-second chair-stand test | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test. |
| Single-leg balance test | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Balance performance will be assessed as the duration of single-leg stance and reported in seconds. |
| Timed up and go test | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down. |
| Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units. |
| Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs) | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units. |
| Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units. |
| Changes in SOCS3 protein expression in PBMCs | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units. |
| Changes in white blood cell count | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Total white blood cell count will be measured and reported in cells/μL. |
| Changes in lymphocyte count | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Lymphocyte count will be measured and reported in cells/μL. |
| Changes in neutrophil count | Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining | Neutrophil count will be measured and reported in cells/μL. |
Countries
Taiwan
Contacts
CONTACTShun-Hsi Tsai, Ph.D.
PRINCIPAL_INVESTIGATORShun-Hsi Tsai, Ph.D.
National Taipei University
Outcome results
None listed